Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 5, 2024European Journal of NeurologyOpen Access

Comparative effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYen‐Feng WangNational Yang Ming Chiao Tung UniversityFYFu‐Chi YangNational Defense UniversityLCLu‐An ChenMackay Memorial Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e65f99b6db6435875edbadhttps://doi.org/10.1111/ene.16372
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adherence to oral migraine-preventive medications among patients with chronic migraine2014 · 441 citations
  2. 2Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study2024 · 29 citations
  3. 3An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study2019 · 107 citations
  4. 4OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine2022 · 38 citations
  5. 5Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine2020 · 109 citations